Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Advanced melanoma treatment has been revolutionized by immunotherapy and targeted therapy.
• Immune checkpoint inhibitors significantly improve survival but are effective in only ~50% of patients.
• Primary or secondary resistance limits the effectiveness of immunotherapy for many melanoma patients.

Purpose of the Study:

• To present current data on biological factors influencing melanoma response to immunotherapy.
• To focus on signaling pathways regulating anti-tumor immune response.
• To discuss the predictive capacity of these biological factors.

Main Methods:

• Review of current data on biological factors affecting immunotherapy response.
• Analysis of factors related to melanoma cells (PD-L1, HLA, mutational load, signaling pathways, epigenetics).
• Evaluation of tumor microenvironment (inflammatory status, immune cell infiltration) and patient-specific features (metabolome, SNPs).

Main Results:

• Response to immunotherapy is influenced by melanoma cell characteristics, tumor microenvironment, and patient-specific factors.
• Key factors include PD-L1 and HLA expression, mutational load, signaling pathway activity, tumor "hot" or "cold" status, and patient metabolome/genetics.
• Signaling pathways play a crucial role in regulating the anti-tumor immune response.

Conclusions:

• Biological factors offer potential for predicting melanoma response to immunotherapy.
• Further research into these factors can help personalize treatment strategies.
• Understanding resistance mechanisms is key to improving patient outcomes in advanced melanoma.